Abstract
Guidelines recommend that patients (pts) undergoing bioprosthetic aortic valve replacement (AVR) receive at least 3 months of anticoagulation with warfarin because it is believed to reduce thromboembolic events. We sought to determine the risk of events in such pts treated and not treated with
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
